Azercabtagene zapreleucel

艾泽妥基仑赛

Report date: 2024/08/12 11:49:28

Base Information

Drug NameAzercabtagene zapreleucel
Drug Alias Nameazer-celPBCAR-0191
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV6 vector
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesMultiple SclerosisHematologic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesKincell Bio LLCImugene LtdBaxalta Incorporated +[5] 
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesMultiple SclerosisHematologic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A